De-escalation Antimicrobial Chemotherapy in Critically Ill Patients: Pros and Cons

References

• Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infections in critically ill patients. Excess length of stay, extra cost, and attributable mortality. JAMA 1994; 271: 1598–1601.
   Google Scholar
• Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical Intensive Care Units in the United States. Infect Control Hosp Epidemiol 2000; 21: 510–515.
   PubMed Web of Science ®Google Scholar
• Leibovici L, Samra Z, Konigsberger H, et al. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807–812.
   PubMed Web of Science ®Google Scholar
• Jones GR, Lowes JA. The systemic inflammatory response syndrome as predictor of bacteraemia and outcome from sepsis. Q J Med 1996; 89: 515–522.
   Google Scholar
• Rello J, Gallego M, Mariscal D, et al. The value of rou-tine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196–200.
   PubMed Web of Science ®Google Scholar
• Perl TM. The threat of vancomycin resistance. Am J Med 1999; 106 (5A): 26S-37S.
   Google Scholar
• Bhorade SM, Christenson J, Pohlman AS, et al. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest 1999; 115 (4): 1085–1091.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Doern CV, et al. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility pat-terns from the Sentry Antimicrobial Surveillance Program. Antimicrob Agents Chemother 1998; 42: 1762–1770.
   PubMed Web of Science ®Google Scholar
• Celis R, Torres A, Gatell JM, et al. Nosocomial pneu-monia: a multivariate analysis of risk and prognosis. Chest 1988; 93: 318–324.
   PubMed Web of Science ®Google Scholar
• Karnad A, Alvarez S, Berk SL. Pneumonia caused by gram-negative bacilli. Am J Med 1985; 79 (1A): 61-67.
   Google Scholar
• Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 11: 676–685.
   Web of Science ®Google Scholar
• Chastre J, Trouillet JL. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 2000; 15 (4): 287–298.
   PubMedGoogle Scholar
• Co ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344: 1329–1332.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Edmond MB, Pfaller MA, et al. Nosocomial bloodstream infections caused by Acinetobacter species in United States Hospitals: clinical features, molecular epidemiology and antimicrobial susceptibility. Clin Infect Dis 2000; 31: 690–697.
   PubMed Web of Science ®Google Scholar
• Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6 (6): 294–302.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F. Efficacy of meropenem as monother-apy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13 (1): 70–81.
   PubMed Web of Science ®Google Scholar
• Lemmen SW, Hafner H, Reinert RR, et al. Comparison of serum bactericidal activity of ceftazidime, ciprofloxacin and meropenem against Sternotrophomonas maltophilia. J Antimicrob Chemother 2001; 47 (1): 118–20.
   PubMed Web of Science ®Google Scholar
• Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacil-li in Intensive Care Units in 5 European countries. JAMA 1999; 281: 67–71.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Garau J, Lode H, et al. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11 (2): 93–100.
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infec-tions on patient outcomes in the ICU setting. Chest 2000; 118: 146–155.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Hospital-acquired pneumo-nia in adults: diagnosis, assessment of severity, initial antimi-crobial therapy, and preventive strategies. Am J Respir Crit Care Med 1995; 153: 1711–1725.
   Web of Science ®Google Scholar
• Gonzales C, Margarita R, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin- susceptible organisms. Clin Infect Dis 1999; 29: 1171–1177.
   PubMed Web of Science ®Google Scholar
• Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methi-cillin-resistant and methicillin-sensible episodes. Am J Respir Crit Care Med 1994; 150: 1545–1549.
   PubMed Web of Science ®Google Scholar
• Georges H, Leroy O, Alfandari S, et al. Pulmonary dis-position of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997; 16: 385–388.
   PubMed Web of Science ®Google Scholar
• Romero-Vivas J, Rubio M, Fernandez C, et al. Mortality associated with nosocomial bacteremia due to methi-cillin resistant Staphylococcus aureus. Clin Infect Dis 1995; 21: 1417–1423.
   PubMed Web of Science ®Google Scholar
• Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treat-ment sites. Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160: 608–613.
   PubMed Web of Science ®Google Scholar
• Froggart JW, Johnston JL, Galetto DW, et al. Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 1989; 33: 460–466.
   PubMed Web of Science ®Google Scholar
• Sanyal D, Johnson AP, George RC, et al. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. (Letter). Lancet 1991; 337–354.
   Google Scholar
• Goldstein FW, Coutrot A, Sieffer A, et al. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 1990; 34: 899–900.
   PubMed Web of Science ®Google Scholar
• Kloos WE, Bannerman TL. Update on clinical signifi-cance of coagulase-negative staphylococci. Clin Microbiol Rev 1994; 7: 117–140.
   PubMed Web of Science ®Google Scholar
• Stroud L, Edwards J, Danzig L, et al. Risks factors for mortality associated with enterococcal bloodstream infections. Infect Contr Hosp Epidemiol 1996; 17: 576–580.
   PubMed Web of Science ®Google Scholar
• Mainous MR, Lipsett PA, O'Brien M, et al. Enterococcal bacteremia in the surgical intensive care unit: does vancomycin resistance affect mortality? Arch Surg 1997; 132: 76–81.
   PubMed Web of Science ®Google Scholar
• Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of van-comycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21: 45–50.
   PubMed Web of Science ®Google Scholar
• Albanese J, Leone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of van-comycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 11 (5): 1356–1358.
   Web of Science ®Google Scholar
• Di Filippo A, De Gaudio AR, Novelli A, et al. Continuous infusion of vancomycin in methicillin-resistant Staphylococcus infection. Chemotherapy 1998; 44 (1): 63–68.
   PubMed Web of Science ®Google Scholar